Salman Punekar, MD
About
Research
Publications
2025
Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).
Garrido-Laguna I, Wolpin B, Park W, Azad N, Spira A, Starodub A, Sommerhalder D, Punekar S, Herzberg B, Barve M, Pelster M, Valerin J, Hecht J, Vora R, Hegde A, Gustafson C, Tao L, Kar S, Lin K, Hong D. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). Journal Of Clinical Oncology 2025, 43: 722-722. DOI: 10.1200/jco.2025.43.4_suppl.722.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaPhase 1 studyOverall survivalRAS mutationsTreatment-related adverse eventsMetastatic pancreatic ductal adenocarcinomaAdministered orally to patientsMedian overall survivalMulti-agent chemotherapyPlasma samplesPhase 3 trialOrally to patientsPaired plasma samplesVariant allele fractionMedian OSEscalating dosesData cutoffSecond-lineCtDNA analysisPeripheral edemaDose optimizationReport safetyMucosal inflammationTargeted therapyEVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).
Spencer K, Punekar S, Grierson P, Mitchell J, Lin Y, Biachi de Castria T, Zhen D, Vu P, Morelli M, Kundranda M, Dorigo O, Maloney D, Ward J, Eng C, Maus M, Simeone D, Welch J, Molina J, Go W, Hecht J. EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2025, 43: tps788-tps788. DOI: 10.1200/jco.2025.43.4_suppl.tps788.Peer-Reviewed Original ResearchOff-tumor toxicityCAR-T therapyPancreatic cancerHLA-A*02T cellsSolid tumorsCAR-TT therapyNormal cellsChimeric antigen receptor T cellsRecommended phase 2 doseT cell receptor therapyNon-small cell lungCryopreserved T cellsPhase 2 doseDose-expansion phaseProgression-free survivalTumor-associated antigensCAR-T activityObjective of Phase 1First-in-humanOverall response rateOn-targetDose escalationMSLN expression
2024
588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH
Grierson P, Punekar S, Hazim A, Welling T, Simeone D, Kirtane K, Lim K, Morelli M, Patel S, Ulrickson M, Biachi de Castria T, Kundranda M, Vong J, Mitchell J, Langeberg W, Maus M, Bretzlaff W, Nikiforow S, Mardiros A, Maloney D, Liechty K, Locke F, Ng E, Randolph Hecht J, Go W, Molina J. 588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH. 2024, a670-a671. DOI: 10.1136/jitc-2024-sitc2024.0588.Peer-Reviewed Original Research627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Molina J, Hazim A, Dorigo O, Punekar S, Avila M, Simeone D, Kirtane K, Konecny G, Ward J, Block M, Specht J, Boyd L, Lou Y, Park J, Xuan J, Eskander R, Ong G, Davila M, Langeberg W, Maus M, Mardiros A, Locke F, Wise A, Maloney D, Welch J, Randolph Hecht J. 627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity. 2024, a721-a722. DOI: 10.1136/jitc-2024-sitc2024.0627.Peer-Reviewed Original Research662 A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumors
Mitchell S, Khan B, Payumo F, Gabriela Chiorean E, Gahvari Z, Randolph Hecht J, Hurwitz M, Leidner R, Lenz H, Pelster M, Schoenfeld A, Punekar S, Zhao D, Basu S, Nagorsen D. 662 A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumors. 2024, a759-a759. DOI: 10.1136/jitc-2024-sitc2024.0662.Peer-Reviewed Original ResearchEP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment
Liu Y, Ma Z, Moreira A, Chachoua A, Velcheti V, Lau S, Punekar S, Sabari J, Shum E. EP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment. Journal Of Thoracic Oncology 2024, 19: s631-s632. DOI: 10.1016/j.jtho.2024.09.1187.Peer-Reviewed Original Research1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
Yap T, Dowlati A, Dagogo-Jack I, Vibert J, Spira A, Garcia V, Punekar S, Calvo E, Sonpavde G, Awad M, Riess J, Hernández-Guerrero T, Herzberg B, Italiano A, Swalduz A, LoRusso P, Smit E, Garon E, Novotny W, Guo R. 1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation. European Journal Of Cancer 2024, 211: 114530. DOI: 10.1016/j.ejca.2024.114530.Peer-Reviewed Original Research514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Wolpin B, Hong D, Spira A, Starodub A, Park W, Sommerhalder D, Valerin J, Barve M, Punekar S, Pelster M, Herzberg B, Azad N, Aung K, Hecht J, Cheng L, Vora R, Salman Z, Zhang Y, Lin T, Garrido-Laguna I. 514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). European Journal Of Cancer 2024, 211: 114992. DOI: 10.1016/j.ejca.2024.114992.Peer-Reviewed Original Research603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
Guo R, Dowlati A, Dagogo-Jack I, Vibert J, Spira A, Garcia V, Punekar S, Calvo E, Sonpavde G, Awad M, Riess J, Guerrero T, Herzberg B, Italiano A, Swalduz A, Lorusso P, Smit E, Garon E, Novotny W, Yap T. 603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation. Annals Of Oncology 2024, 35: s483-s484. DOI: 10.1016/j.annonc.2024.08.670.Peer-Reviewed Original ResearchAFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors.
Mitchell S, Khan B, Payumo F, Chiorean E, Gahvari Z, Hecht J, Hurwitz M, Leidner R, Lenz H, Pelster M, Punekar S, Schoenfeld A, Zhao D, Vallaster M, Nagorsen D. AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. Journal Of Clinical Oncology 2024, 42: tps8650-tps8650. DOI: 10.1200/jco.2024.42.16_suppl.tps8650.Peer-Reviewed Original ResearchOptimal biological doseCD8+ T cellsAutologous CD4+Advanced/metastatic solid tumorsT cellsSolid tumorsSwitch receptorsDose expansionDose escalationCD4+Transgenic TCRMechanism of actionDose-limiting toxicity observation periodRecommended phase 2 doseT cell cytotoxic activityIncreased T cell activationCD4+ T cellsHelper T cell responsesPreventing T cell exhaustionPost-treatment follow-up periodChimeric switch receptorsPhase 2 doseImmunosuppressive tumor microenvironmentT cell exhaustionDuration of response